Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Shockwave Medical, Inc. - Common Stock
(NQ:
SWAV
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Shockwave Medical, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
This Stock Is Up 106% In 2022 And Analysts Love It, But Jim Cramer Says 'There's Too Much Political Risk'
↗
November 15, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a "very early stage company that has a lot in the pipe. I tend to like these companies."
Via
Benzinga
2 Stocks I'd Buy Right Now Without Hesitation
↗
November 13, 2022
One's a growth stock and the other pays a dividend but both of these healthcare businesses have what it takes to reliably outperform.
Via
The Motley Fool
Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review
↗
November 11, 2022
Bitcoin hit a two-year low while Meta and Tesla were in focus.
Via
Investor's Business Daily
Here's the Best Growth Stock to Buy Right Now If You're Worried About a Recession
↗
November 09, 2022
Macroeconomic pressures aren't much of an issue when all your customers are cardiovascular surgeons.
Via
The Motley Fool
ShockWave Medical (SWAV) Q3 2022 Earnings Call Transcript
↗
November 07, 2022
SWAV earnings call for the period ending September 30, 2022.
Via
The Motley Fool
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
↗
November 08, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Where ShockWave Medical Stands With Analysts
↗
November 08, 2022
Over the past 3 months, 4 analysts have published their opinion on ShockWave Medical (NASDAQ:SWAV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...
Via
Benzinga
Shockwave Medical Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Shockwave Medical, Inc.
Via
GlobeNewswire
Earnings Preview: ShockWave Medical
↗
November 04, 2022
ShockWave Medical (NASDAQ:SWAV) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that ShockWave...
Via
Benzinga
Earnings Scheduled For November 7, 2022
↗
November 07, 2022
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
Via
Benzinga
Best and Worst Performing Stocks Since Rate Hikes Began
↗
November 02, 2022
Looking at the S&P 1500, which includes large-caps, mid-caps, and small-caps, the average stock in the index is down 7.1% since the close on March 16th after the first rate hike.
Via
Talk Markets
Shockwave Confirms Consistent Outcomes for IVL in the Largest Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease
November 01, 2022
Disrupt PAD III Observational Study Results Confirm Safety and Effectiveness of IVL in Patients with Complex Calcified Lesions
From
Shockwave Medical, Inc.
Via
GlobeNewswire
Ranking 7 Top Tech Stocks to Buy From Biggest to Smallest
↗
October 28, 2022
Although "Big Tech" is currently struggling, but there are still many good top tech stocks to buy at this point.
Via
InvestorPlace
Nasdaq Bear Market: 3 Growth Stocks You'll Regret Not Buying at Knocked-Down Prices
↗
October 25, 2022
Scooping up shares of these fast-growing businesses on the dip could do wonders for your portfolio over time.
Via
The Motley Fool
Opportunities In Large Cap Growth And Small Cap
↗
October 20, 2022
The third quarter was true
Via
Talk Markets
Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2022 Results
October 20, 2022
From
Shockwave Medical, Inc.
Via
GlobeNewswire
7 Little-Known Stocks With Millionaire-Maker Potential
↗
October 14, 2022
The unprecedented number of tech revolutions has made it easier than ever to identify many potential millionaire-maker stocks to buy.
Via
InvestorPlace
Eli Lilly Leads 5 Stocks To Watch In Bear Market
↗
October 08, 2022
Eli Lilly is holding up, while others crumbled Friday amid the market sell-off.
Via
Investor's Business Daily
2 Medical Device Makers Crushing the Market
↗
October 06, 2022
One company is an industry disruptor with big upside potential, while the other is a huge, diversified company.
Via
The Motley Fool
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
↗
October 05, 2022
Biotech isn't the only place to make money in health care this year.
Via
Investor's Business Daily
Cutera Stock Earns Relative Strength Rating Upgrade
↗
October 03, 2022
On Monday, medical aesthetic Cutera stock had its Relative Strength (RS) Rating upgraded to 90 from 80 a day earlier.
Via
Investor's Business Daily
Expert Ratings for ShockWave Medical
↗
August 29, 2022
Over the past 3 months, 5 analysts have published their opinion on ShockWave Medical (NASDAQ:SWAV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...
Via
Benzinga
Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday
↗
August 29, 2022
Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
↗
September 06, 2022
Upgrades
Via
Benzinga
ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?
August 25, 2022
Shockwave Medical bolted 40% higher since its second-quarter earnings report on August 8. It's currently trading at new highs, but is it the right time to buy?
Via
MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
↗
August 12, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
↗
August 12, 2022
The major indexes continued to advance, despite some key warnings.
Via
Investor's Business Daily
InMode Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
↗
August 09, 2022
On Tuesday, InMode stock got a positive adjustment to its Relative Strength (RS) Rating, to 86 from 72 a day earlier.
Via
Investor's Business Daily
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
↗
August 10, 2022
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Via
Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
↗
August 09, 2022
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.